There is insufficient evidence for the efficacy of comprehensive multiple risk factor interventions by pharmacists in the primary prevention of cardiovascular disease (CVD). Given the proven benefits of pharmacist interventions for individual risk factors, ft is essential that evidence for a comprehensive approach to care be generated so that pharmacists remain key members of the health care team for individuals at risk of initial onset of CVD.
Objective:
To establish the feasibility of an intervention delivered by community pharmacists to reduce the risk of primary onset of CVD.
Methods:
A single-cohort intervention study was undertaken in 2008–2009. Twelve community pharmacists from 10 pharmacies who were trained to provide lifestyle and medicine management support to reduce CVD risk recruited 70 at-risk participants aged 50-74 years who were free from diabetes or CVD. Participants received a baseline assessment to establish CVD risk and health behaviors. An assessment report provided to patients and pharmacists was used to collaboratively establish treatment goals and, over 5 sessions, implement treatment strategies. Follow-up assessment at 6 months measured changes in baseline parameters. The primary outcome was the average change to overall 5-year risk of CVD onset
Results:
Sixty-seven participants were included In the analysis. The mean participant age was 60 years and 73% were female. We observed a 25% (95% CI 17 to 33) proportional risk reduction in overall CVD risk. Significant reductions also occurred in mean blood pressure (–11/–5 mm Hg) and waist circumference (-1.3 cm), with trends toward improvement for most other observed risk factors.
Conclusions:
Findings support previous evidence of positive cardiovascular health outcomes following pharmacist intervention in other patient groups; we recommend generating randomized controlled trial evidence for a primary prevention population.
LopezAD, BeggS, BosE.Global burden of disease and risk factors. In: LopezAD, MathersCD, EzzatiM, JamisonDT, MurrayCJL, eds. Demographic and epidemiological characteristics of major regions, 1990–2001. Oxford: Oxford University Press/World Bank, 2006.
2.
RoseG.Sick individuals and sick populations. Int J Epidemiol1985;14:32–8. DOI 10.1093/ije/14.132
3.
VartiainenEA, LaatikainenT, PhilpotB, JanusED, Davis-LameloiseN, DunbarJA. The projected impact of population and high-risk strategies for risk-factor control on coronary heart disease and stroke events. Med J Aust2011;194:10–5.
4.
MachadoM, BajcarJ, GuzzoGC, EinarsonTR. Sensitivity of patient outcomes to pharmacist interventions. Part I: systematic review and meta-analysis in diabetes management. Ann Pharmacother2007;41:1569–82. DOI 10.1345/aph.1K151
5.
CliffordRM, DavisWA, BattyKT, DavisTME. Effect of a pharmaceutical care program on vascular risk factors in type 2 diabetes. Diabetes Care2005;28:771–6. DOI 10.2337/diacare.28.4.771
6.
KoshmanSL, CharroisTL, SimpsonSH, McAlisterFA, TsuyukiRT. Pharmacist care of patients with heart failure: a systematic review of randomized trials. Arch Intern Med2008;168:687–94. DOI 10.1001/archinte.168.7.687
7.
KrassI, ArmourCL, MitchellB. The Pharmacy Diabetes Care Pro gram: assessment of a community pharmacy diabetes service model in Australia. Diabet Med2007;24:677–83. DOI 10.1111/j.1464-5491.2007.02143.x
8.
MachadoM, BajcarJ, GuzzoGC, EinarsonTR. Sensitivity of patient outcomes to pharmacist interventions. Part II: systematic review and meta-analysis in hypertension management. Ann Pharmacother2007;41:1770–81. DOI 10.1345/aph.1K311
9.
MachadoM, NassorN, BajearJM, GuzzoGC, EinarsonTR. Sensitivity of patient outcomes to pharmacist interventions. Part III: systematic review and meta-analysis in hyperlipidemia management. Ann Pharmacother2008;42:1195–207. DOI 10.1345/aph.1K618
10.
HoulihanF, KrassI, ChenT.Rural community pharmacy: a feasible site for a health promotion and screening service for cardiovascular risk factors. Aust J Rural Health2003;11:28–35. DOI 10.1046/j.1440-1584.2003.00468A
11.
HorganJMP, BlenkinsoppA, McManusRJ. Evaluation of a cardiovascular disease opportunistic risk assessment pilot (“Heart MOT” service) in community pharmacies. J Public Health2010;32:110–6. DOI 10.1093/pubmed/fdp092
MoscaL, BenjaminEJ, BerraK. Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: a guideline from the American Heart Association. Circ2011;123:1243–62. DOI 10.1161/CIR.0b013e31820faaf8
14.
GrahamI, AtarD, Borch-JohnsenK. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J2007;28:2375–414. DOI 10.1093/eurheartj/ehm316
15.
World Health Organisation.Prevention of cardiovascular disease: guidelines for assessment and management of total cardiovascular risk. Geneva: WHO, 2007.
16.
McNamaraK, GeorgeJ, O'reillyS. Engaging community pharmacists in the primary prevention of cardiovascular disease: protocol for the Pharmacist Assessment of Adherence, Risk and Treatment in Cardiovascular Disease (PAART CVD) pilot study. BMC Health Serv Res2010;10:264. DOI 10.1186/1472-6963-10-264
17.
SchwarzerR.Modeling health behavior change: how to predict and modify the adoption and maintenance of health behaviors. Applied Psychology2008;57:1–29. DOI 10.1111/j.1464-0597.2007.00325.x
18.
LaatikainenT, DunbarJA, ChapmanA. Prevention of type 2 diabetes by lifestyle intervention in an Australian primary health care setting: Greater Green Triangle (GGT) Diabetes Prevention Project. BMC Public Health2007;7:249. DOI 10.1186/1471-2458-7-249
19.
AbsetzP, ValveR, OldenburgB. Type 2 diabetes prevention in the ‘real world.’ Diabetes Care 2007;30:2465–70. DOI 10.2337/dc07-0171
20.
TolonenH, KuulasmaaK, LaatikainenT, WolfH.European Health Risk Monitoring project. Recommendation for indicators, international collaboration, protocol and manual of operations for chronic disease risk factor surveys, 2002. http://www.ktl.fi/publications/ehrm/product2/title.htm (accessed 2007 May 16).
21.
WHO MONICA Project Principal Investigators.The World Health Organization MONICA project (MONItoring trends and determinants in CArdiovascular disease): a major international collaboration. J Clin Epidemiol 1988;41:105–14. DOI 10.1016/0895-4356(88)90084-4
MoriskyDE, GreenLW, LevineDM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care1986;24:67–74. DOI 10.1097/00005650-198601000-00007
24.
GeorgeJ, MackinnonA, KongDCM, StewartK.Development and validation of the Beliefs and Behaviour Questionnaire (BBQ). Patient Educ Counsel2006;64:50–60. DOI 10.1016/j.pec.2005.11.010
25.
Kinect Australia for the Lifescripts consortium.Lifescripts practice manual: supporting lifestyle risk factor management in general practice. Canberra Commonwealth of Australia, 2005.
26.
BushK, KivlahanDR, McDonellMB, FihnSD, BradleyKA, for the Ambulatory Care Quality Improvement Project. The AUDIT alcohol consumption questions (AUDJT-C): an effective brief screening test for problem drinking. Arch Intern Med1998;158:1789–95. DOI 10.1001/archinte.158.16.1789
27.
RadioffLS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psych Meas1977;1:385–401. DOI 10.1177/014662167700100306
28.
WareJE, KosinskiM, Turner-BowkerDM, GandeckB.User's manual for the SF-12v2 Health Survey. Boston: Quality Metrics, 2007.
29.
O'ReillyS, McCannL.Development and validation of the Diet Quality Tool for use in cardiovascular disease prevention settings. Australian Journal of Primary Care (published online), http://dx.doi.org/10.1071/PY11005 (accessed 2011 Nov 18).
30.
AndersonKM, OdellPM, WilsonPW, KannelWB. Cardiovascular disease risk profiles. Am Heart J1991;121:293–8. DOI 10.1016/0002-8703(91)90861-B
31.
ManuelDG, LimJ, TanuseputroP. Revisiting Rose: strategies for reducing coronary heart disease. BMJ2006;332:659–62. DOI 10.1136/bmj.332.7542.659
32.
EbrahimS, TaylorF, WardK, BeswickA, BurkeM, Davey SmithG.Multiple risk factor interventions for primary prevention of coronary heart disease. Cochrane Database of Syst Rev2011: Issue 1. Art. No. CD001561. DOI 10.1002/14651858.CD001561.pub3
LiuY, MenteleLJ, McDonoughRP, CarruthersKM, DoucetteWR. Community pharmacist assessment of 10-year risk of coronary heart disease for union workers and their dependents. J Am Pharm Assoc2008;48:515–7.
35.
MangumSA, KraenowKR, NarducciWA. Identifying at-risk patients through community pharmacy-based hypertension and stroke prevention screening projects. J Am Pharm Assoc2003;43:50–5. DOI 10.1331/JAPhA.2008.07099
36.
SantscV, ChioleroA, BurnandB, ColosimoAL, ParadisG.Impact of pharmacist care in the management of cardiovascular disease risk factors: a systematic review and meta-analysis of randomized trials. Arch Intern Med2011;171:1441–53. DOI 10.1001/archinternmed2011.399
37.
BuntingB, SmithB, SutherlandS.The Asheville Project: clinical and economic outcomes of a community-based long-term medication therapy management program for hypertension and dyslipidemia. J Am Pharm Assoc2008;48:23–31. DOI 10.1331/JAPhA.2008.07140
38.
Wolf-MaierK, CooperRS, KramerH. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertens2004;43:10–7. DOI 10.1161/01.HYP.0000103630.72812.10
39.
LaatikainenT, DunbarJ, ChapmanA. Prevention of type 2 diabetes by lifestyle intervention in an Australian primary health care setting: Greater Green Triangle (GGT) Diabetes Prevention Project. BMC Public Health2007;7:249. DOI 10.1186/1471-2458-7-249
40.
HebertJR, ClemowL, PbertL, OckeneIS, OckeneJK. Social desirability bias in dietary self-report may compromise the validity of dietary intake measures. Int J Epidemiol1995;24:389–98. DOI 10.1093/ije/24.2.389
41.
SteinJH, CarlssonCM, Papcke-BensonK, EinersonJA, McBridePE, WiebeDA. Inaccuracy of lipid measurements with the portable Cholestech LDX Analyzer in patients with hypercholesterolemia. Clin Chem2002;48:284–90.
